J.P. Morgan Chase & Co. (NYSE: JPM) still has ambitions of increasing its dividend. The bank also wants to increase its share buybacks. This is an important step because Jamie Dimon and team did not get the full permission that was sought under the capital allocation plan by regulators in the wake of the London Whale debacle which cost the banking giant billions of dollars and which tarnished the reputation of the bank.
Now we have Chief Financial Officer Marianne Lake having made new comments on Monday that seem to champion the move toward higher dividends and buybacks yet again. She was presenting at the Barclays Global Financial Services Conference. One other note is that the banking giant has now increased its legal reserves as well by what we evaluated as over $1.5 billion, due largely to mortgage-backed securities litigation and other regulatory issues acting against the bank.
J.P. Morgan earnings will be released on October 11, 2013. J.P. Morgan shares have been somewhat range-bound of late, and the gain on Monday of 0.3% compares to a 52-week trading range of $38.73 to $56.93. Its dividend yield is 2.9% based upon the latest $0.38 per share per quarter payout. Be advised that this July payment was the first $0.38 payout after having been at $0.30 per share for five prior quarters.
Top 10 Low Price Companies To Own In Right Now: MER Telemanagement Solutions Ltd.(MTSL)
Mer Telemanagement Solutions Ltd., together with its subsidiaries, designs, develops, markets, and supports a line of telecommunication expense management (TEM), and customer care and billing solutions for business organizations and other enterprises worldwide. Its TEM solutions assist enterprises and organizations in the allocation of costs, budget control, fraud detection, processing of payments, and spending forecasting. The company also offers converged billing solutions, including applications for charging and invoicing customers, interconnect billing, and partner revenue management through pre-pay and post-pay schemes for wireless providers, voice over Internet protocol, Internet protocol television, and content service providers. Its products provide telecommunication and information technology managers with tools to reduce communication costs, recover charges payable by third parties, and to detect and prevent abuse and misuse of telephone networks comprising fault telecommunication usage. The company markets its products through its direct sales force, distributors, and business telephone switching systems manufacturers and vendors. Mer Telemanagement Solutions Ltd. was founded in 1995 and is headquartered in Raanana, Israel.
Advisors' Opinion:- [By James E. Brumley]
Trading can be a quirky game sometimes. Most of the time, news - or at least loudly voiced opinions - tend to result from or be the cause of a fast-moving stock. Every now and then though, as in the case with MER Telemanagement Solutions Ltd. (NASDAQ:MTSL), a stock can build up steam with little to no news linked to that move. That doesn't make that stock a poor pick, however. Indeed, MTSL looks like it's turning into a homerun, and that alone is worth a look.... and maybe even worth a shot.
- [By Bryan Murphy]
If you're a small cap enthusiast looking for some budding ideas, you may not need to look any further than China GengSheng Minerals, Inc. (NYSEMKT:CHGS), Bio Matrix Scientific Group Inc. (OTCMKTS:BMSN), and MER Telemanagement Solutions Ltd. (NASDAQ:MTSL). All three have either pushed themselves to the brink of a breakout, if they haven't started one already. Here's a closer technical look at MTSL, BMSN, and CHGS, and what it's going to take to get them going if they're not going already.
Top Electric Utility Stocks For 2014: Medtronic Inc (MDT)
Medtronic, Inc. (Medtronic), incorporated on April 23, 1957, is engaged in medical technology - alleviating pain, restoring health, and extending life for millions of people worldwide. As of April, 27, 2012, the Company functions in two operating segments that manufacture and sells device-based medical therapies. The Company's operating segments include Cardiac and Vascular Group, which consists of Cardiac Rhythm Disease Management (CRDM) and CardioVascular, and Restorative Therapies Group, which consists of Spinal, Neuromodulation, Diabetes and Surgical Technologies. Medtronic serves hospitals, physicians, clinicians, and patients in more than 120 countries worldwide. The Company's primary customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. In August 2013, Medtronic, Inc. announced the closing of the acquisition of Cardiocom. Effective September 3, 2013, Medtronic Inc acquired a 30% stake in NGC Medical SpA.
Cardiac Rhythm Disease Management
CRDM develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), and information systems for the management of patients with CRDM devices. The Company's principal products offered by CRDM business include Implantable Cardiac Pacemakers (Pacemakers), Implantable Cardioverter Defibrillators (ICDs), Implantable Cardiac Resynchronization Therapy Devices (CRT-Ds and CRT-Ps), AF Products, Diagnostics and Monitoring Devices and Patient Management Tools. The Company's pacemaker systems are compatible with certain magnetic resonance imaging (MRI) machines. This includes the Revo MRI SureScan with United States Food and Drug Administration approval and the Advisa and Ensura MRI SureScan models with Conformite Europeene (CE)! Mark approval. Medtronic also continues to market the Adapta product family, which includes the Adapta, Versa, Sensia, and Relia models.
The Medtronic ICDs is the Protecta family with SmartShock technology, including the Lead Integrity Alert, a technology designed to improve the detection of lead fractures. Devices in the ICD family are the Protecta XT, Protecta, Cardia, and Egida models. Medtronic also continues to market the Secura and Maximo II devices. The Medtronic CRT-Ds is the Protecta family with SmartShock technology, including Protecta XT and Protecta, and the CRT-P devices are Consulta and Syncra. Medtronic also continues to market the Consulta, Cardia, Egida, and Maximo II CRT-D devices. In addition to these devices, Medtronic has an offering of left heart leads and delivery catheters with its Attain family of products. The Company's portfolio of AF products includes the Arctic Front Cardiac CryoAblation Catheter designed to treat paroxysmal AF by performing pulmonary vein isolation. The Company also offers the Reveal XT Insertable Cardiac Monitor, which is designed to identify and quantify episodes of AF. The Reveal DX and Reveal XT Insertable Cardiac Monitors devices are used to record the heart's electrical activity before, during, and after transient symptoms such as syncope and palpitations to help provide a diagnosis. It has a number of patient management tools, such as CareLink, Paceart, and CardioSight Service. CareLink enables patients to transmit data from their pacemaker, ICD, CRT-D, or Insertable Cardiac Monitors using a portable monitor that is connected to a standard telephone line or cellular network using the Medtronic M-Link accessory.
The Company competes with St. Jude Medical, Inc., Boston Scientific Corporation, Biotronik, Inc. and Sorin Group.
CardioVascular
CardioVascular is comprised of three businesses: Coronary, Endovascular and Peripheral, and Structural Heart. The Coronary business includes therapies to treat ! coronary ! artery disease (CAD) and hypertension. The products contained within this business include coronary stents and related delivery systems, along with a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters, and accessories. The products offered by its Coronary business include Percutaneous Coronary Intervention (PCI) and Renal Denervation. The Endovascular and Peripheral business is comprised of a range of products and therapies to treat abdominal and thoracic aortic aneurysms and peripheral vascular disease (PVD). The Company's products include endovascular stent graft systems, embolic protection systems, and stent systems for the treatment of narrowed iliac arteries. The products offered by the Company's Endovascular and Peripheral business include Endovascular Stent Grafts and Peripheral Vascular Intervention (PVI). The Structural Heart business offers a range of products and therapies to treat a variety of heart valve disorders. The Company's products include products for the repair and replacement of heart valves, perfusion systems, positioning and stabilization systems for beating heart revascularization surgery, and surgical ablation products. The Company's principal products offered by its Structural Heart business include Heart Valves, Transcatheter Heart Valves, Arrested Heart Surgery, Beating Heart Surgery and Surgical Ablation.
The Company competes with Abbott Laboratories, Boston Scientific, and Johnson & Johnson, Cook, Inc., W. L. Gore & Associates, Inc., Endologix, Inc., C.R. Bard, Inc., Edwards LifeSciences Corporation, St. Jude, Terumo Medical Corporation and Sorin Group.
Spinal
The Company's Spinal business develops, manufactures, and markets a range of medical devices and implants used in the treatment of the spine and musculoskeletal system. The Company's products and therapies treat a range of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumours, fractures ! of the sp! ine, and stenosis. The Company's Spinal business also provides biologic solutions for the dental and orthopedic markets. The Company's Spinal products are used in spinal fusion of both the thoracolumbar region, referring to the mid to lower vertebrae, as well as of the cervical region, or upper spine and neck vertebrae. Products used to treat spinal conditions include rods, pedicle screws, hooks, plates, and interbody devices, as well as biologics products, primarily bone growth substitutes including bone graft extenders and structural allografts such as dowels and wedges. The products offered by the Company's Spinal business include Thoracolumbar Products, Cervical Products and Biologics Products.
The Company competes with DePuy Spine, Inc., Synthes, Inc., Stryker Corporation, NuVasive, Inc., Globus Medical, Inc., Zimmer, Inc., Alphatec Spine, Inc., Orthofix International N.V., Biomet, Inc. and Johnson & Johnson.
Neuromodulation
The Company's Neuromodulation business develops, manufactures, and markets medical devices for the treatment of chronic pain, movement disorders, psychological disorders, and urological, fecal, and gastroenterological disorders. The l products offered by the Company's Neuromodulation business includes Neurostimulators for Chronic Pain, Implantable Drug Delivery Systems, Deep Brain Stimulation (DBS) Systems and Urology, Fecal, & Gastroenterology Devices. The Company's portfolio of products includes the RestoreSensor (rechargeable), with the Company's AdaptiveStim technology, as well as the RestoreULTRA (rechargeable), RestoreADVANCED (rechargeable), and PrimeADVANCED (non-rechargeable) neurostimulation systems. The SynchroMed II Programmable Infusion System delivers small quantities of drug directly into the intrathecal space surrounding the spinal cord. These devices are used to treat chronic, intractable pain and severe spasticity associated with cerebral palsy, multiple sclerosis, spinal cord and traumatic brain injuries, and stroke.
DBS uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver carefully controlled electrical stimulation to precisely targeted areas in the brain. The Company's family of Activa Neurostimulators for DBS includes Activa SC (single-channel primary cell), Activa PC (dual channel primary cell), and Activa RC (dual channel rechargeable). The Company's therapeutic portfolio for urology and gastroenterology includes the InterStim Therapy System, which treats the symptoms of overactive bladder, urinary retention, and chronic fecal incontinence, and the Enterra Therapy System for the treatment of chronic nausea and vomiting caused by gastroparesis of diabetic or idiopathic origin for drug refractory patients.The Company's competes with Boston Scientific, St. Jude., Urologix, Inc. and Allergan.
Diabetes
The Company's Diabetes business develops, manufactures, and markets advanced, integrated diabetes management solutions that include insulin pump therapy, continuous glucose monitoring systems, and therapy management software. The products offered by the Company's Diabetes business includes Integrated Diabetes Management Solutions, Professional CGM and CareLink Therapy Management Software. Outside the United States, the Company offers its Paradigm Veo System, an integrated system that includes a Low Glucose Suspend feature that automatically suspends insulin delivery when glucose levels become too low. In the United States, the Company offers the Paradigm Revel System, which incorporates new CGM features, including predictive alerts that can give early warning to people with diabetes so they can take action to prevent dangerous high or low glucose events. Medtronic offers physicians a Professional CGM product called the iPro CGM and iPro2 Professional CGM. The Company offers Web-based therapy management software solutions, including CareLink Personal software for patients and CareLink Pro software, to helps patients and their health care prov! iders con! trol their diabetes.
The Company competes with DexCom, Inc., Insulet Corporation, Johnson & Johnson and Roche Ltd.
Surgical Technologies
The Company's Surgical Technologies business develops, manufactures, and markets products and therapies to treat diseases and conditions of the ear, nose, and throat (ENT) and certain neurological disorders. In addition, the business develops, manufactures, and markets image-guided surgery and intra-operative imaging systems that facilitate surgical planning during precision cranial, spinal, sinus, and orthopedic surgeries. The products offered by the Company's Surgical Technologies business includes ENT, Neurological Technologies, Navigation and Advanced Energy. The ENT products treat diseases and conditions, such as NIM Nerve Monitoring Systems, Fusion ENT Navigation System, Hydrodebrider Endoscopic Sinus Irrigation System, Meniett Device for Meniere's Disease, Pillar Procedure for Snoring and Sleep Apnea, and Repose System for Obstructive Sleep Apnea. The Neurological Technologies products treat certain neurological disorders and conditions, such as Midas Rex Spine Shaver, the Midas Rex MR7 Pneumatic Platform, the Midas Rex Legend EHS High Speed Surgical Drill, the Strata Family of Adjustable Valves for the treatment of Hydrocephalus, Duet External Drainage & Monitoring System, the IPC System, and the Subdural Evacuating Port System.
The Navigation products are used in cranial, spinal, sinus, and orthopedic surgeries, such as the StealthStation S7 Navigation and i7 Integrated Navigation Systems, the O-Arm 2D/3D Surgical Imaging System, and the PoleStar Surgical MRI System. The products make up the Advanced Energy business: PEAK Surgery System, a tissue dissection system that consists of the PEAK PlasmaBlade and the PULSAR Generator and is cleared for use in a variety of settings, including ENT, plastic reconstructive and general surgery; and the Aquamantys System, which uses patented Transcollation technology to ! provide h! aemostatic sealing of soft tissue and bone and is cleared for use in a range of surgical procedures, including orthopedic surgery, spine, solid organ resection and thoracic procedures.
The Company competes with Gyrus ACMI, Stryker Corporation, Johnson & Johnson, Integra LifeSciences Holdings Corporation, BrainLAB, Inc., GE Healthcare, Siemens Medical Solutions USA, Inc., Philips Medical Systems, Covidien and ArthroCare Corporation.
Advisors' Opinion:- [By Teresa Rivas]
Shares of Edward Lifesciences (EW) were climbing as high as 15% in Monday morning trading, after a federal court late Friday sided with the firm in its patent infringement lawsuit against Medtronic�(MDT). The decision stipulated an injunction against the sale of Medtronic�� Transcatheter valves, although the firm plans to appeal the ruling. (Medtronic, by contrast, was falling 4.2%.)
- [By Ben Levisohn]
While shares of Volcano have dropped 15% to $20.74, large-cap medical device companies are having a solid day. Boston Scientific (BSX) has gained 1.4% to 11.74, St. Jude Medical (STJ) has risen 0.9% to $48.13 and Medtronic (MDT) has ticked up 0.1% to $57.73.
- [By Michael A. Robinson]
I'm talking about the Minneapolis-based Medtronic Inc. (NYSE: MDT), a company that I've followed for many years.
Medtronic is the world's largest independent medical technology company. About half of the company's business is devoted to heart-problem treatments. The rest is apportioned among vascular diseases, diabetes, neurological conditions, surgical technologies, and spinal care.
- [By Gregory Wallace]
Inversion can yield significant tax savings. One of the most recent deals, for example, shifts medical device giant Medtronic (MDT) from Minneapolis to Ireland, where it acquired rival Covidien. Ireland's corporate tax rate of 12.5% is significantly lower than the top U.S. rate of 35%. Pfizer (PFE) recently pursued a similar deal with its British pharmaceutical rival AstraZeneca (AZN).
Top Electric Utility Stocks For 2014: Kirkland's Inc.(KIRK)
Kirkland?s, Inc. operates as a specialty retailer of home decor and gifts in the United States. Its stores offer various merchandise, including framed art, mirrors, wall decor, candles and related items, lamps, decorative accessories, accent furniture, textiles, garden-related accessories, and artificial floral products. The company?s stores also provide an assortment of holiday merchandise during seasonal periods, as well as items suitable for gift-giving. It operates stores under the Kirkland?s, Kirkland?s Home, Kirkland?s Home Outlet, and Kirkland?s Outlet names. The company operates its stores in enclosed malls and various off-mall venues, including lifestyle centers, power strip centers, outlet centers, and freestanding locations. Kirkland?s, Inc. also sells its products through its Web site kirklands.com. As of March 08, 2012, it operated 299 stores in 30 states. The company was founded in 1966 and is based in Nashville, Tennessee.
Advisors' Opinion:- [By Seth Jayson]
Margins matter. The more Kirkland's (Nasdaq: KIRK ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong Kirkland's competitive position could be.
- [By Laura Brodbeck]
Thursday
Earnings Expected From: AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), Kirkland��, Inc (NASDAQ: KIRK), Dollar General Corporation (NYSE: DG), Stein Mart, Inc. (SMRT: NASDAQ), Mattress Firm Holding Corp. (NASDAQ: MRFM), SeaWorld Entertainment (NYSE: SEAS), Vaalco Energy Inc (NYSE: EGY) Economic Releases Expected: Chinese retail sales, French CPI, Brazilian retail sales, US retail sales, Japanese industrial productionFriday
Top Electric Utility Stocks For 2014: Kindred Healthcare Inc. (KND)
Kindred Healthcare, Inc. operates as a healthcare services company in the United States. The company�s Hospital division operates long-term acute care (LTAC) and inpatient rehabilitation (IRFs) hospitals, which provide services to medically complex patients, including the critically ill, suffering from multiple organ system failures, primarily the cardiovascular, pulmonary, kidney, gastro-intestinal, and skin systems, as well as life-threatening infections. Its Nursing Center division operates nursing and rehabilitation centers, and assisted living facilities that offer short stay patients and long stay residents with a range of medical, nursing, rehabilitative, pharmacy, and routine services. It also provides specialized programs for residents suffering from Alzheimer�s disease and other dementias through its reflections units. The company�s Rehabilitation division provides rehabilitation services, including physical and occupational therapies, and speech pathology ser vices under the RehabCare name to residents and patients of nursing centers, LTAC hospitals, outpatient clinics, home health agencies, assisted living facilities, school districts, and hospice providers. In addition, it offers specialized care programs that address medical needs, such as wound care, pain management, and cognitive retraining; and programs for neurologic, orthopedic, cardiac, and pulmonary conditions. Its Home Health and Hospice division offers home health, hospice, and private duty services to patients in various settings comprising homes, skilled nursing facilities, and other residential settings. As of December 31, 2011, it operated 121 LTAC hospitals with 8,597 licensed beds, and 5 IRFs with 183 licensed beds in 26 states; and 224 nursing and rehabilitation centers with 27,148 licensed beds, and 6 assisted living facilities with 413 licensed beds in 27 states. The company was founded in 1998 and is headquartered in Louisville, Kentucky.
Advisors' Opinion:- [By Justin Loiseau]
Kindred Healthcare (NYSE: KND ) announced today that it is selling eight nursing centers for around $49 million to privately run Signature Healthcare.
No comments:
Post a Comment